ALPS Medical Breakthroughs ETF $SBIO Shares Sold by Exencial Wealth Advisors LLC

Exencial Wealth Advisors LLC lessened its stake in shares of ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) by 19.5% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 7,735 shares of the company’s stock after selling 1,868 shares during the period. Exencial Wealth Advisors LLC’s holdings in ALPS Medical Breakthroughs ETF were worth $233,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of SBIO. Rossby Financial LCC acquired a new position in shares of ALPS Medical Breakthroughs ETF during the 1st quarter worth about $147,000. Moran Wealth Management LLC acquired a new position in shares of ALPS Medical Breakthroughs ETF during the 2nd quarter worth about $300,000. Strategic Financial Services Inc. raised its position in shares of ALPS Medical Breakthroughs ETF by 12.7% during the 1st quarter. Strategic Financial Services Inc. now owns 19,225 shares of the company’s stock worth $548,000 after purchasing an additional 2,163 shares during the last quarter. Jones Financial Companies Lllp acquired a new position in shares of ALPS Medical Breakthroughs ETF during the 1st quarter worth about $782,000. Finally, Phoenix Financial Ltd. acquired a new position in shares of ALPS Medical Breakthroughs ETF during the 1st quarter worth about $41,785,000.

ALPS Medical Breakthroughs ETF Stock Performance

SBIO opened at $42.48 on Friday. ALPS Medical Breakthroughs ETF has a twelve month low of $22.33 and a twelve month high of $43.60. The company has a 50-day moving average price of $37.96 and a 200 day moving average price of $32.84.

ALPS Medical Breakthroughs ETF Profile

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.